Evidence map›Paper›PMID 36506569›Full record

ReviewFrontiers in pharmacology2022

Research progress in traditional Chinese medicine in the treatment of Alzheimer's disease and related dementias.

Wanying Tan, Lingjun Qi, Xiaoyu Hu, Zhenghuai Tan

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Frontiers in pharmacology · 2023
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Frontiers in pharmacology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Frontiers in aging neuroscience · 2024
    Article
  19. 4,4'-methylenediphenol reduces Aβ-induced toxicity in aFrontiers in aging neuroscience · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wanying TanHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lingjun QiSichuan Academy of Traditional Chinese Medicine, Chengdu, China.
Xiaoyu HuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhenghuai TanSichuan Academy of Traditional Chinese Medicine, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the world's leading cause of dementia and has become a huge economic burden on nations and families. However, the exact etiology of AD is still unknown, and there are no efficient medicines or methods to prevent the deterioration of cognition. Traditional Chinese medicine (TCM) has made important contributions in the battle against AD based on the characteristics of multiple targets of TCM. This study reviewed the treatment strategies and new discoveries of traditional Chinese medicine in current research, which may be beneficial to new drug researchers.

Indexed as

Alzheimer’s diseaseepimediumginsengPueraria lobatatraditional Chinese medicine

Identifiers

PMID36506569
PMCPMC9729772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.